이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biofrontera 과거 수익 실적

과거 기준 확인 0/6

Biofrontera의 수입은 연평균 -11.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 0.4%의 비율로 감소했습니다. 매출은 연평균 15.7%의 비율로 증가해 왔습니다.

주요 정보

-11.3%

수익 성장률

48.3%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	15.7%
자기자본 수익률	n/a
순이익	-69.4%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

May 24

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

Dec 30

The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Nov 13

Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Oct 18

Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours

Oct 05

Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation

Sep 06

Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance

Aug 12

Biofrontera announces 2Q prelim product revenues

Jul 12

수익 및 비용 분석

Biofrontera 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:BFRI 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	33	-23	38
31 Dec 23	34	-20	38
30 Sep 23	34	-26	38
30 Jun 23	29	-23	36
31 Mar 23	28	-14	36
31 Dec 22	29	-1	35
30 Sep 22	28	-12	24
30 Jun 22	28	-26	33
31 Mar 22	29	-29	29
31 Dec 21	24	-38	26
30 Sep 21	24	-23	32
30 Jun 21	22	-10	19
31 Mar 21	19	-10	17
31 Dec 20	19	-11	18
31 Dec 19	26	-11	28

양질의 수익: BFRI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: BFRI 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: BFRI 은(는) 수익성이 없으며 지난 5년 동안 연간 11.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 BFRI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: BFRI 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 19.9% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: BFRI 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Biofrontera 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Biofrontera Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Biofrontera Inc. to Report Q4, 2023 Results on Mar 15, 2024

Biofrontera Inc. to Report Q4, 2023 Results on Mar 06, 2024

Biofrontera Inc. to Report Q3, 2023 Results on Nov 09, 2023

Recent updates

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Consensus EPS estimates fall by 31%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Biofrontera Inc. to Report Q1, 2024 Results on May 15, 2024

Biofrontera Inc., Annual General Meeting, Jun 12, 2024

Consensus EPS estimates upgraded to US$3.25 loss, revenue downgraded

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS exceeds analyst expectations

Biofrontera Inc. to Report Q4, 2023 Results on Mar 15, 2024

Forecast to breakeven in 2025

New minor risk - Profitability

Biofrontera Inc. announced that it has received $8 million in funding

Biofrontera Inc. announced that it has received $8 million in funding

Biofrontera Inc. announced that it expects to receive $8 million in funding

Biofrontera Inc. announced that it expects to receive $8 million in funding

Biofrontera Inc. announced that it expects to receive $8 million in funding

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

New major risk - Shareholder dilution

Nasdaq Determines to Grant Biofrontera Inc. an Extension of 180 Calendar Days from November 22, 2023 to Regain Compliance

Biofrontera Inc. has filed a Follow-on Equity Offering in the amount of $4.5 million.

Biofrontera Inc. to Report Q4, 2023 Results on Mar 06, 2024

Forecast to breakeven in 2026

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

New major risk - Share price stability

Biofrontera Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Continued Listing Requirement Under Nasdaq Listing Rule 5550(b)(1)

Biofrontera Inc., Annual General Meeting, Dec 20, 2023

New minor risk - Profitability

The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023

Biofrontera Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Market cap size

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Consensus EPS estimates fall by 26%

Biofrontera Inc. Affirms Guidance for 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-Pdt for the Treatment of Basal Cell Carcinoma

Biofrontera Inc. to Report Q2, 2023 Results on Aug 11, 2023

New major risk - Share price stability

New minor risk - Profitability

Biofrontera Inc. Provides Preliminary Revenue Guidance for the Second Quarter, First Half and Full-Year of 2023

Biofrontera Inc. Appoints Heikki Lanckriet to Its Board of Directors

Biofrontera Announces 1-For-20 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Biofrontera Notifies Nasdaq Regarding its No Longer in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Biofrontera Inc. Announces Resignation of Erica Monaco, Chief Executive Officer

Consensus revenue estimates fall by 12%

Full year 2022 earnings released: US$0.002 loss per share (vs US$4.28 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Forecast breakeven date moved forward to 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Biofrontera Inc. Revises Revenue Guidance for the Year 2022

Biofrontera Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biofrontera Inc., Annual General Meeting, Dec 12, 2022

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Biofrontera Inc. Reports Preliminary Product Revenues for the Third Quarter and Nine Months Ended September 30, 2022

Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours

Biofrontera Inc. Appoints Gerard Digirolamo as National Sales Director

Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation

Biofrontera Inc. Provides Earnings Guidance for the Fiscal Year of 2022

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.46 loss in 2Q 2021)

Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance

Biofrontera Inc. to Report Q2, 2022 Results on Aug 12, 2022

Biofrontera Inc. Provides Revenue Guidance for the Second Quarter and Six Months Ended June 30, 2022